X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Tazarotene-Generic (tazarotene) topical 0.1% cream is used to help reduce fine facial wrinkles and certain types of dark and light spots on the face in patients who use a total skin care program and avoid sunlight. Tazarotene topical cream and gel are used to treat psoriasis.
Lead Product(s): Tazarotene
Therapeutic Area: Dermatology Product Name: Tazarotene-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
ARAZLO® (tazarotene) Lotion, 0.045% is a prescription medicine used on the skin (topical) to treat people 9 years of age and older with acne, which can include blackheads, whiteheads, and other pimples.
Lead Product(s): Tazarotene
Therapeutic Area: Dermatology Product Name: Arazlo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
The presentations will feature new efficacy and safety analyses of ARAZLO® (tazarotene) Lotion, 0.045%, long-term outcomes of DUOBRII® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, quality of life improvement with SILIQ® (brodalumab) injection.
Lead Product(s): Halobetasol,Tazarotene
Therapeutic Area: Dermatology Product Name: Duobrii
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
When administered together in DUOBRII, they provide complementary effects due to their individual modes of action targeting different receptors and pathways to achieve anti-inflammatory control and epidermal morphologic restoration.
Lead Product(s): Halobetasol,Tazarotene
Therapeutic Area: Dermatology Product Name: Duobrii
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
